Clinical partnerships Opportunity to pursue collaborations with Radiopharm Theranostics and its active clinical programs in RAD202 RAD101 RAD204; potential to offer imaging and radiopharmaceutical sourcing, contract research, or technology licensing to support trial workflows and biomarker analytics.

Strategic funding Company has substantial funding and revenue indicators, suggesting readiness for co-development deals, joint ventures, or milestone-based partnerships with diagnostic imaging platforms or assay development services to accelerate trial timelines.

Imaging expertise Strong focus on radiopharmaceutical imaging and diagnostic agents; cross-sell opportunities for companion diagnostics, MRI/PET integration, and analytics tools to enhance patient selection and treatment monitoring in oncology.

Clinical data leverage Recent trial progress and positive results indicate a data-rich environment; offer data management, biostatistics, and real-world evidence services to support regulatory submissions, market access, and product commercialization.

Geographic expansion Global activity including US and Australia signals openness to international trials and supply arrangements; explore regional GMP manufacturing support, regulatory consulting, and distributed testing services to scale operations.